Literature DB >> 12225297

Validity of a rheumatic disease diagnosis in the Medical Birth Registry of Norway.

Johan Skomsvoll1, Monika Østensen, Valborg Baste, Lorentz Irgens.   

Abstract

BACKGROUND: In our population-based study of pregnancy outcome in women with rheumatic disease we based our assessment on the Medical Birth Registry of Norway (MBRN). We evaluated the MBRN as a source of data for such epidemiologic research by assessing the validity of a diagnosis of rheumatic disease in the MBRN against a gold standard. The validity may also be interpreted as a quality indicator, reflecting an obstetrician's attention to rheumatic diseases in pregnancy.
METHODS: Using the mother's national identification number the MBRN was linked with local hospital databases (gold standard), which contained data of mothers with rheumatic disease. The sensitivity of the MBRN was calculated as the proportion of all cases registered locally with a diagnosis of rheumatic disease notified to the MBRN. The correctness of type differentiation was calculated as the proportion of all cases notified to the MBRN that was correct with respect to the type of rheumatic disease.
RESULTS: Among 169 mothers, 149 had a diagnosis in the MBRN, representing a sensitivity of 88.2%. Altogether, 97.3% of the diagnoses (145/149) were correct with respect to the type of rheumatic disease.
CONCLUSION: Taken in to consideration the limitations of the study, namely the small numbers studied, we assume a rather high validity of rheumatic disease diagnoses in the MBRN, probably reflecting a high level of attention in the obstetric care for these patients.

Entities:  

Mesh:

Year:  2002        PMID: 12225297     DOI: 10.1034/j.1600-0412.2002.810905.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  8 in total

1.  Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy.

Authors:  Gyri Veiby; Anne Kjersti Daltveit; Bernt A Engelsen; Nils Erik Gilhus
Journal:  J Neurol       Date:  2014-01-22       Impact factor: 4.849

2.  Maternal Chronic Conditions and Risk of Cerebral Palsy in Offspring: A National Cohort Study.

Authors:  Marianne S Strøm; Mette C Tollånes; Allen J Wilcox; Rolv Terje Lie; Ingeborg Forthun; Dag Moster
Journal:  Pediatrics       Date:  2021-03       Impact factor: 7.124

3.  The validity of the diagnosis of inflammatory arthritis in a large population-based primary care database.

Authors:  Markus M J Nielen; Jennie Ursum; François G Schellevis; Joke C Korevaar
Journal:  BMC Fam Pract       Date:  2013-06-07       Impact factor: 2.497

4.  Reproductive trends in females with inflammatory joint disease.

Authors:  Marianne Wallenius; Kjell Å Salvesen; Anne K Daltveit; Johan F Skomsvoll
Journal:  BMC Pregnancy Childbirth       Date:  2016-05-31       Impact factor: 3.007

5.  Elective cesarean section or not? Maternal age and risk of adverse outcomes at term: a population-based registry study of low-risk primiparous women.

Authors:  Lina Herstad; Kari Klungsøyr; Rolv Skjærven; Tom Tanbo; Lisa Forsén; Thomas Åbyholm; Siri Vangen
Journal:  BMC Pregnancy Childbirth       Date:  2016-08-17       Impact factor: 3.007

6.  Low risk pregnancies after a cesarean section: Determinants of trial of labor and its failure.

Authors:  Sjur Lehmann; Elham Baghestan; Per E Børdahl; Lorentz M Irgens; Svein Rasmussen
Journal:  PLoS One       Date:  2020-01-13       Impact factor: 3.240

7.  Maternal complications in pregnancy and childbirth for women with epilepsy: Time trends in a nationwide cohort.

Authors:  Kim Christian Danielsson; Nils Erik Gilhus; Ingrid Borthen; Rolv Terje Lie; Nils-Halvdan Morken
Journal:  PLoS One       Date:  2019-11-25       Impact factor: 3.240

8.  Hyperemesis gravidarum in the Medical Birth Registry of Norway - a validity study.

Authors:  Åse Vikanes; Per Magnus; Siri Vangen; Sølvi Lomsdal; Andrej M Grjibovski
Journal:  BMC Pregnancy Childbirth       Date:  2012-10-24       Impact factor: 3.007

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.